LXR activation may inhibit NF-κB and its downstream inflammatory cytokines, such as IL-T, TNF-α, and iNOS, which could improve PAH-induced cardiac hypertrophy and remodeling. The gene discussed is NFKB1; the disease is cardiac hypertrophy.